Simplex Trading’s Candel Therapeutics CADL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$141K Buy
13,500
+3,500
+35% +$38.8K ﹤0.01% 5032
2026
Q2
$103K Sell
10,000
-19,500
-66% -$147K ﹤0.01% 5510
2026
Q1
$145K Buy
29,500
+22,100
+299% +$120K ﹤0.01% 4672
2025
Q4
$41.8K Buy
7,400
+4,900
+196% +$26.4K ﹤0.01% 5827
2025
Q3
$12K Sell
2,500
-15,100
-86% -$87.3K ﹤0.01% 7738
2025
Q2
$89K Sell
17,600
-73,200
-81% -$377K ﹤0.01% 5350
2025
Q1
$513K Buy
90,800
+62,300
+219% +$509K ﹤0.01% 3374
2024
Q4
$247K Buy
28,500
+20,300
+248% +$120K ﹤0.01% 4284
2024
Q3
$56K Buy
8,200
+6,000
+273% +$37.3K ﹤0.01% 5784
2024
Q2
$13K Buy
+2,200
New +$16.5K ﹤0.01% 7229

Other funds holding CADL

Simplex Trading's CADL Position: Q3 2026 in Review

Simplex Trading increased its Candel Therapeutics (CADL) stake by 50% in Q3 2026, buying an estimated $9.8K and bringing the position to 2,631 shares worth $27.5K. The position accounts for ﹤0.01% of the portfolio, ranked #6772.

Simplex Trading first reported a position in CADL in Q2 2024 and has held it in 7 quarters since. The position peaked at $158K in Q3 2024. 141 funds tracked by Wall St. Rank hold CADL as of Q3 2026.

  • Simplex Trading held 2,631 shares of Candel Therapeutics worth $27.5K as of Q3 2026.
  • Simplex Trading bought 882 Candel Therapeutics shares in Q3 2026, an estimated $9.8K.
  • Candel Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q3 2026, its #6772 holding.
  • Simplex Trading first reported a position in Candel Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • Simplex Trading's Candel Therapeutics position peaked at $158K in Q3 2024.
  • 141 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2026.

Based on Simplex Trading's 13F filing for Q3 2026, filed 4 Nov 2026.